Literature DB >> 16631007

Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization.

Maurizio Pieroni1, Cristina Chimenti, Francesco De Cobelli, Emanuela Morgante, Alessandro Del Maschio, Carlo Gaudio, Matteo Antonio Russo, Andrea Frustaci.   

Abstract

OBJECTIVES: We sought to identify echocardiographic hallmarks of Fabry's disease cardiomyopathy (FC).
BACKGROUND: The recognition of FC from other forms of left ventricular hypertrophy (LVH) by noninvasive imaging techniques is not yet available, and diagnosis, mostly in the absence of systemic manifestations, still relies on genetic and invasive studies.
METHODS: Forty consecutive patients (mean age 39 +/- 15 years, 22 men and 18 women) with an established diagnosis of Fabry's disease were submitted to echocardiographic evaluation. Control population consisted of 40 consecutive patients with hypertrophic cardiomyopathy (HCM), 40 hypertensive patients with echocardiographic evidence of LVH, and 40 age- and gender-matched healthy subjects with no LVH. All HCM patients and FC with LVH and/or cardiac symptoms underwent cardiac catheterization with left ventricular endomyocardial biopsy.
RESULTS: Echocardiography showed in 83% of FC patients (95% of FC patients with LVH) a binary appearance of endocardial border absent in all HCM, hypertensive, and healthy subjects. The sensitivity and specificity of this echocardiographic feature in detecting Fabry patients in study population were 94% and 100%, respectively. Comparison of echocardiographic with histologic and ultrastructural findings showed the binary appearance to reflect an endomyocardial glycosphingolipids compartmentalization, consisting of thickened glycolipid-rich endocardium, free glycosphingolipid subendocardial storage, and an inner severely affected myocardial layer with a clear subendocardial-midwall layer gradient of disease severity.
CONCLUSIONS: Echocardiographic binary appearance of left ventricular endocardial border, reflecting endomyocardial glycosphingolipids compartmentalization, represents a sensitive and specific diagnostic hallmark of Fabry's disease cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631007     DOI: 10.1016/j.jacc.2005.11.070

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

Review 1.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

Review 2.  Fabry disease.

Authors:  Toshinori Yuasa; Toshihiro Takenaka; Koji Higuchi; Nami Uchiyama; Yoshihisa Horizoe; Hideto Cyaen; Naoko Mizukami; Kunitsugu Takasaki; Akira Kisanuki; Masaaki Miyata; Mitsuru Ohishi
Journal:  J Echocardiogr       Date:  2017-07-03

Review 3.  Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment.

Authors:  Maria-Angela Losi; Stefano Nistri; Maurizio Galderisi; Sandro Betocchi; Franco Cecchi; Iacopo Olivotto; Eustachio Agricola; Piercarlo Ballo; Simona Buralli; Antonello D'Andrea; Arcangelo D'Errico; Donato Mele; Susanna Sciomer; Sergio Mondillo
Journal:  Cardiovasc Ultrasound       Date:  2010-03-17       Impact factor: 2.062

Review 4.  Fabry disease: raising awareness of the disease among physicians.

Authors:  Francesca Carubbi; Lisa Bonilauri
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

5.  Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease.

Authors:  Cristina Chimenti; Nazha Hamdani; Nicky M Boontje; Francesco DeCobelli; Antonio Esposito; Jean G F Bronzwaer; Ger J M Stienen; Matteo A Russo; Walter J Paulus; Andrea Frustaci; Jolanda van der Velden
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

6.  Chloroquine cardiomyopathy: beyond ocular adverse effects.

Authors:  Nilson Lopez-Ruiz; Carlos Esteban Uribe
Journal:  BMJ Case Rep       Date:  2014-09-15

Review 7.  Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain.

Authors:  Hidekazu Tanaka
Journal:  J Echocardiogr       Date:  2021-01-18

Review 8.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

9.  Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.

Authors:  Taciane Alegra; Filippo Vairo; Monica V de Souza; Bárbara C Krug; Ida V D Schwartz
Journal:  Genet Mol Biol       Date:  2012-12-18       Impact factor: 1.771

Review 10.  Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.

Authors:  Roberta Esposito; Ciro Santoro; Giulia Elena Mandoli; Vittoria Cuomo; Regina Sorrentino; Lucia La Mura; Maria Concetta Pastore; Francesco Bandera; Flavio D'Ascenzi; Alessandro Malagoli; Giovanni Benfari; Antonello D'Andrea; Matteo Cameli
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.